New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Johnson & Johnson

JNJ

Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

271.02 3.92 +1.47%
Market cap
$650.7B
P/E
40.5×
Fwd P/E FY26e
41.8×
Dividend yield
1.98%
F-score
3/9
ROIC
11.1%
Net debt / EBITDA
0.5×
Payout ratio
0.8×

Johnson & Johnson (JNJ) EPS (diluted)

Alert me on EPS (diluted)

Johnson & Johnson's EPS (diluted) for fiscal 2025 was $11.03, up 90.5% from $5.79 in fiscal 2024. Over the twelve months to Sep 30, 2026 it was $6.60. Over the past ten years it has ranged from $0.47 (fiscal 2017) to $13.72 (fiscal 2023); the current reading is higher than 91% of that period. Johnson & Johnson ranks 4th of 20 Drug Manufacturers General companies by EPS (diluted).

EPS (diluted), annual

Embed this chart

Annual newest first

Period EPS (diluted) Change
FY2025 $11.03 90.50%
FY2024 $5.79 (57.80%)
FY2023 $13.72 103.86%
FY2022 $6.73 (13.83%)
FY2021 $7.81 41.74%
FY2020 $5.51 (2.13%)
FY2019 $5.63 0.36%
FY2018 $5.61 1,093.62%
FY2017 $0.47 (92.07%)
FY2016 $5.93 8.21%

Quarterly newest first

Period EPS (diluted) Change
Sep 2026 $0.09 (96.04%)
Jun 2026 $2.27 6.07%
Mar 2026 $2.14 1.90%
Dec 2025 $2.10 (0.94%)
43 more quarters

Against its own ten years

Low $0.47 High $13.72
Ten-year median $5.79
Current reading's percentile 91

EPS (diluted) against peers

What EPS (diluted) is

Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.

Reported line item

The full definition of EPS (diluted) →

More on JNJ